Oracle forecasts $225 billion in fiscal 2030 revenue and caps new funding at $20 billion

2 min read
Oracle forecasts $225 billion in fiscal 2030 revenue and caps new funding at $20 billion
PrimeXBT Editorial Team
Reviewed by PrimeXBT

Oracle shares rose on Wednesday after the company forecast $225 billion in fiscal 2030 revenue and capped new funding at $20 billion. Its CFO also said free cash flow should turn positive in the second half of fiscal 2028.

Oracle shares jumped on Wednesday after the software company issued a revenue forecast of $225 billion for fiscal 2030. The target implies 35% average annual growth. Shares were up more than 8% in afternoon trading, after falling around a third so far this year.

Funding limited to $20 billion

Oracle also said it committed to limit additional funding for fiscal 2027 through 2030 to $20 billion. It expects that total to be divided equally between equity and debt.

The company said in an SEC filing that vendor financing, customer-provided hardware and customer prepayments are expected to reduce upfront cash requirements during the transition to positive free cash flow.

Cash flow turn set for fiscal 2028

CFO Hilary Maxson said at the investor day that Oracle expects free cash flow to turn positive in the second half of fiscal 2028. She said it should exceed $30 billion in fiscal 2029 as capital spending declines.

Oracle has become a focal point of investor worries about the cost of AI infrastructure, according to Reuters. The agency notes the company relies heavily on a single customer, OpenAI.

Targets for fiscal 2027 and 2030

For fiscal 2030, Oracle also forecast an adjusted operating margin above 40% and adjusted earnings per share of more than $21. It reaffirmed its fiscal 2027 forecast of more than $90 billion in revenue and adjusted earnings of $8.10 per share.

Analysts polled by LSEG had expected growth of 8% in fiscal 2027, followed by significant acceleration over the next two years.

Sources: CNBC, Reuters via Investing.com

Trading involves risk.

Most traded markets

XAU / USD
+0.23% 4,069.64
CRUDE
+1.25% 102.783
BTC / USD
+1.01% 81,519.2
EUR / USD
+0.27% 1.11564
USTEC
+0.71% 29,841.72
XAU / USD.24
+0.23% 4,069.64
View all markets

Author

PrimeXBT
Our Editorial Team consists of leading experts with a proven record in the fields of trading, cryptocurrencies, blockchain and finance. We thoroughly research the sources of information in order to provide readers with quality content that serves edu...
Read author’s articles
Alert Triangle Risk Disclaimer
Disclaimer: Some past publications may be outdated. We recommend following our news to stay up to date with the latest information. For any questions, feel free to contact our support team via the chat below.
The content provided here is for informational purposes only. It is not intended as personal investment advice and does not constitute a solicitation or invitation to engage in any financial transactions, investments, or related activities. Past performance is not a reliable indicator of future results.
The financial products offered by the Company are complex and come with a high risk of losing money rapidly due to leverage. These products may not be suitable for all investors. Before engaging, you should consider whether you understand how these leveraged products work and whether you can afford the high risk of losing your money.
The Company does not accept clients from the Restricted Jurisdictions as indicated in our website/ T&C. Some services or products may not be available in your jurisdiction.
The applicable legal entity and its respective products and services depend on the client’s country of residence and the entity with which the client has established a contractual relationship during registration.

Today in markets

Browse Stock News

Register Now

Trading involves risk

Get started in minutes

Our clients love how fast and simple our sign-up is. It takes just a few minutes to get started!

Get Started Get Started
Get started in minutes

Need Help?

Risk Warning:
Trading in leveraged products carries a high level of risk and may not be suitable for all investors.